Factors Influencing the Efficacy of Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer

Corresponding author: yangyingtao, yangyingtao001@126.com

DOI: 10.12201/bmr.202511.00048

•  

  Abstract: Objective To investigate the factors influencing the efficacy of neoadjuvant chemotherapy in patients with human epidermal growth factor receptor-2 (HER2)-negative breast cancer. Methods A retrospective analysis was conducted using clinical data from 79 HER2-negative breast cancer who received preoperative neoadjuvant chemotherapy at the Fifth Affiliated Hospital of Zhengzhou University from December 2020 to December 2024. The efficacy of neoadjuvant chemotherapy was evaluated according to the pathological Miller-Payne grading system after surgery. Using the chi-square test to analyze the relationship between the clinicopathological data and their therapeutic efficacy, and binary Logistic regression analysis was used to find the factors influencing therapeutic efficacy. Results Patients were divided into the G1~G3 group (n=50) and the G4~G5 group (n=29). Univariate analysis showed that the marker of proliferation Ki-67 ≥ 30%, negative axillary lymph nodes, TNM stage Ⅱ, triple-negative breast cancer, HER2-negative, no calcification in the lesion and cytokeratin 5/6 (CK5/6) positive were associated with a better therapeutic efficacy of neoadjuvant chemotherapy (all P values were < 0.05). Multivariate analysis showed that Ki-67 ≥ 30% (OR=4.191，P=0.032), triple-negative breast cancer (OR=6.112，P=0.020) were favorable factors influencing the therapeutic efficacy, while calcification in the lesion was an independent risk factor (OR=0.243，P=0.041). Conclusion The Ki-67 expression level, breast cancer molecular subtype, and the presence or absence of calcification in the lesion canbe looked as effective predictive factors for the efficacy of neoadjuvant chemotherapy in patients with HER2-negative breast cancer. While the HER2 expression level is not an independent factor influencing the efficacy of neoadjuvant chemotherapy.

  Key words: breast cancer; HER2-Negative; neoadjuvant chemotherapy; efficacy.

  Submit time: 19 November 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• ruanxuling, liuqi, guo zhiheng, yanjunfeng. Research on prediction model of breast cancer based on LDA and XGBoost algorithm. 2022. doi: 10.12201/bmr.202106.00007

  Wuhuan, Luoyushuang. Circulating Tumor Cell HER-2 Expression in the Targeted Therapy of Gastric Adenocarcinoma. 2024. doi: 10.12201/bmr.202408.00001

  Yao Genwu, Wang Yanwei, Guo Jinyi, Li Lulu, Dang Wenbo, Song Ailin. Advances in single-cell sequencing in the breast cancer. 2024. doi: 10.12201/bmr.202407.00053

  Yuan Heqing, Shao Xiying. . 2025. doi: 10.12201/bmr.202504.00058

  ma guang fan, chen xiao zhen, zhou sen. Effect of esketamine on early postoperative mental state in patients with breast cancer. 2024. doi: 10.12201/bmr.202412.00054

  quyanli. Efficacy and safety of preoperative chemotherapy in real world patients with locally advanced gastric/gastroesophageal junction adenocarcinoma. 2024. doi: 10.12201/bmr.202409.00052

  Huangwanwei, Huangkaijun, Jianglijun. The Current Status and Influential Factors of Breast Cancer Patients Returning to Work: A Meta-Analysis. 2025. doi: 10.12201/bmr.202509.00042

  li quan, zhu shunpeng, shao hao, ZHOU JINHUA. Experience and Literature Review on Multidisciplinary Collaborative Neoadjuvant Chemotherapy in the Diagnosis and Treatment of Pregnancy-Associated Cervical Cancer. 2025. doi: 10.12201/bmr.202510.00028

  ZHAO Qing, JING Jiangxin. Advances in the application of ultrasound-based radiomics in predicting molecular typing of breast cancer. 2024. doi: 10.12201/bmr.202410.00040

  qianlin, yangyi. Analysis the Medication Regularity of TCM in the Treatment of Breast Cancer in the Real World Based on Data Mining Method. 2025. doi: 10.12201/bmr.202506.00022

• ID	Submit time	Number	Download
  1	2025-11-11	10.12201/bmr.202511.00048V1	Download

• Public  Anonymous  To author only Submit Comments